Sector News

Dr Jessie English joins Merck

January 26, 2016
Life sciences

Merck Jessie EnglishMerck KGaA has appointed Dr Jessie English as its new vice president of discovery, transnational innovation platform immuno-oncology.

She will take up her new role on 16 February, when she will lead the discovery team’s efforts in the exploration of disease targets and translating these into patient care.

Dr English joins Merck from the Belfer Institute for Applied Cancer Sciences at Havard Medical School’s Dana-Farber Cancer Institute where she had been head of research since March 2012.

During her two decades of work in oncology and immune-oncology research, she has also served as vice president of kinase biology at ArQule, oncology site lead for external discoveries at Merck Research Laboratories.

Prior to that she held leadership positions at both Pfizer Research and Schering-Plough Research Institute.

Source: PMLive

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”